drugset
drugset / Trial / NCT05255094

A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia

NCT05255094 ↗

Phase 3 Completed 464 enrolled Akeso
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled phase 3 clinical study evaluating the efficacy and safety of AK102 in patients with primary hypercholesterolemia and mixed hyperlipidemia.

Timeline

Start
2021-11-03
Primary completion
2022-06-22
Completion
2022-06-22

Drugs

EvaluationDrugModalityDoseRoute
Subject AK102 Monoclonal antibody — Subcutaneous

Indications

hyperlipidemia